Afinitor(R) Approved In US As First Treatment For Patients With Advanced Kidney Cancer After Failure Of Either Sunitinib Or Sorafenib

Novartis announced that Afinitor(R) (everolimus) tablets has been approved by the US Food and Drug Administration (FDA) for patients with advanced renal cell carcinoma (RCC) after failure of treatment with Sutent(R) (sunitinib) or Nexavar(R) (sorafenib). Prior to Afinitor, no other therapy has been studied in a Phase III trial in this patient population where there is an important unmet medical need(1). Complete news at...